|
Age | 62 岁 |
|
patients with coronary heart disease | Yes
|
|
Sign the informed consent | Yes
|
|
Risk stratification for patients with low or middle risk | middle risk
|
|
Patients in one of the following condition are excluded | none
|
|
Name | YARH |
|
gender | 男 |
|
people | 汉 |
|
Height | 169 cm |
|
weight | 57.8 kg |
|
abdomen circumference | 82 cm |
|
left ventricular ejection fraction(LVEF) | 62 |
|
stents implanted | No
|
|
anamnesis | hypertension
/arrhythmia
/heart failure
|
|
Body Mass Index | 20.24 kg/m2 |
|
smoking history | Yes
|
|
blood cholesterol level in hospital | 6 mmol/l |
|
drink history | Yes
|
|
Bad mood performance | loneliness
|
|
exercise habit | No
|
|
The drug | antiplatelet drug
/β-Receptor blockers
/statins
|
|
heart rate in anaerobic domain | 次/分 |
|
heart rate in the peak oxygen uptake | 123 次/分 |
|
blood pressure in Anaerobic domain | mm/Hg |
|
blood pressure in the peak oxygen uptake | 181/69 mm/Hg |
|
the oxygen uptake in the rest | 0.260 ml/kg/min |
|
the oxygen uptake in anaerobic threshold | ml/kg/min |
|
Peak oxygen uptake | 1.192 ml/kg/min |
|
target heart rate | 110 次/分 |
|
Treadmill load | 69 w |
|
blood pressure in the rest | 87 次/分 |
|
blood pressure in the rest | 125/68 mm/Hg |
|
Phosphodiesterase 9A | ng/ml |
|
Inflammatory factors | ng/ml |
|
Immune-modulatory marker | ng/ml |
|
left ventricular dysfunction marker | ng/ml |
|
myeloperoxidase | ng/ml |
|
adiponectin | ng/ml |
|
extracellular-matrix remodeling markers | ng/ml |
|
heart rate in anaerobic domain | 次/分 |
|
heart rate in the peak oxygen uptake | 102 次/分 |
|
blood pressure in the rest | mm/Hg |
|
blood lipid level in Peak oxygen uptake period | 153/75 mm/Hg |
|
the oxygen uptake in the rest | 0.297 ml/kg/min |
|
the oxygen uptake in anaerobic threshold | ml/kg/min |
|
Peak oxygen uptake | 1.260 ml/kg/min |
|
target heart rate | 99 次/分 |
|
Treadmill load | 64 w |
|
heart rate in the rest | 73 次/分 |
|
blood pressure in the rest | 123/73 mm/Hg |
|
Phosphodiesterase 9A | ng/ml |
|
Inflammatory factors | ng/ml |
|
Immune-modulatory marker | ng/ml |
|
left ventricular dysfunction marker | ng/ml |
|
myeloperoxidase | ng/ml |
|
adiponectin | ng/ml |
|
extracellular-matrix remodeling markers | ng/ml |
|
Patients with follow-up of 3 months is discomfort or not | No
|
|
stick to exercise or not in the follow-up after 3 months | Yes
|